<?xml version="1.0" encoding="UTF-8"?>
<p>The prevalence of HBV in patients with IBD is not different from that in the general population [
 <xref rid="b51-ir-2019-09155" ref-type="bibr">51</xref>-
 <xref rid="b53-ir-2019-09155" ref-type="bibr">53</xref>]. In all HBV seronegative patients (HBsAg, anti-HBc, and anti-HBs negative) with IBD, regardless of the degree of immunosuppression, HBV vaccination is recommended [
 <xref rid="b2-ir-2019-09155" ref-type="bibr">2</xref>,
 <xref rid="b5-ir-2019-09155" ref-type="bibr">5</xref>]. However, some questions have been raised about whether universal vaccination is necessary in areas with low HBV prevalence [
 <xref rid="b54-ir-2019-09155" ref-type="bibr">54</xref>,
 <xref rid="b55-ir-2019-09155" ref-type="bibr">55</xref>]. The WHO recommended administering the HBV vaccine after birthâ€”in all countries with high, intermediate and low endemicity [
 <xref rid="b56-ir-2019-09155" ref-type="bibr">56</xref>]. Despite these recommendations, the rate of routine HBV vaccination in patients with IBD is not high [
 <xref rid="b53-ir-2019-09155" ref-type="bibr">53</xref>,
 <xref rid="b57-ir-2019-09155" ref-type="bibr">57</xref>], according to a study conducted in Spain involving more than 2,000 patients with IBD, only 12% of patients were administered HBV vaccine [
 <xref rid="b53-ir-2019-09155" ref-type="bibr">53</xref>]. Since HBV infection is relatively common in Korea, specific attention should be given to HBV serology testing and HBV vaccination in patients with IBD.
</p>
